Phio Pharmaceuticals (PHIO) Non Operating Income (2013 - 2025)
Phio Pharmaceuticals' (PHIO) quarterly Non Operating Income came in at $143000.0 in Q2 2025, up 110.29% YoY from $68000.0 in Q2 2024, and up 750.0% on a QoQ basis from -$22000.0 in Q1 2025.
Phio Pharmaceuticals (PHIO) Non Operating Income (2013 - 2025) Analysis & Trends
Phio Pharmaceuticals (PHIO) has 13 years of Non Operating Income data on file, last reported at $143000.0 in Q2 2025.
- Quarterly Non Operating Income rose 110.29% year-over-year to $143000.0 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $255000.0 (up 264.29% YoY) and the FY2023 annual result came in at -$2000.0, up 88.89% from the prior year.
- Non Operating Income rose to $143000.0 in Q2 2025, from -$22000.0 in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $231000.0 in Q1 2021 to a low of -$22000.0 in Q1 2025.
- A 5-year average of $28812.5 and a median of -$1500.0 in 2021 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2021 — Non Operating Income jumped 4520.0% — and 2025, when it tumbled 1200.0%.
- Tracing PHIO's Non Operating Income over 5 years: stood at -$1000.0 in 2021, then changed by 0.0% to -$1000.0 in 2022, then soared by 500.0% to $4000.0 in 2023, then surged by 1550.0% to $66000.0 in 2024, then soared by 116.67% to $143000.0 in 2025.
- The last three Non Operating Income figures came in at $143000.0 (Q2 2025), -$22000.0 (Q1 2025), and $66000.0 (Q3 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Phio Pharmaceuticals | 13.77 Mn | 13.77 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 143,000.00 |
| Mar 31, 2025 | -22,000.00 |
| Sep 30, 2024 | 66,000.00 |
| Jun 30, 2024 | 68,000.00 |
| Mar 31, 2024 | 2,000.00 |
| Dec 31, 2023 | 4,000.00 |
| Sep 30, 2023 | -4,000.00 |
| Jun 30, 2023 | -2,000.00 |
| Dec 31, 2022 | -1,000.00 |
| Sep 30, 2022 | -5,000.00 |
| Jun 30, 2022 | -10,000.00 |
| Mar 31, 2022 | -2,000.00 |
| Dec 31, 2021 | -1,000.00 |
| Sep 30, 2021 | -3,000.00 |
| Jun 30, 2021 | -3,000.00 |
| Mar 31, 2021 | 231,000.00 |
| Sep 30, 2020 | -3,000.00 |
| Jun 30, 2020 | -3,000.00 |
| Mar 31, 2020 | 5,000.00 |
| Dec 31, 2019 | 9,000.00 |